NCT06137157View on ClinicalTrials.gov

Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 19, 2024

Primary Completion Date

February 1, 2026

Study Completion Date

April 1, 2026

Conditions
Netherton Syndrome
Interventions
DRUG

ATR12-351

Topical ointment containing ATR12-351, a LEKTI-secreting strain of S. epidermidis

Trial Locations (2)

94304

RECRUITING

Stanford University, Palo Alto

06519

RECRUITING

Yale University, New Haven

Sponsors

Lead Sponsor

Azitra Inc.
All Listed Sponsors
lead

Azitra Inc.

INDUSTRY

NCT06137157 - Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome | Biotech Hunter | Biotech Hunter